ASH Abstracts Reveal How AI-Driven Biosimulation Technology Predicts Drug Response in Individual Cancer Patients with High Accuracy
SAN JOSE, Calif. November 19, 2018 – Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer of Therapy Response Index (TRI) technology, today announced that results from using its genomics-informed Computational Biology Modeling technology (CBM) to predict drug response within specific cancer tumors will be featured as 10 poster presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition held December 1-4, 2018 in San Diego, California.
“Over the past year, we have completed many studies using our AI-driven biosimulation technology to predict drug responses for tumors based the genomic data of each cancer patient,” said Yatin Mundkur, CEO of Cellworks. “The consistent high accuracy of these studies demonstrates tremendous promise for using AI-driven biosimulation to match the best therapy to individual patients the first time. This approach avoids the side-effects, costs and risks associated with nonresponsive treatments, and ultimately saves lives. We look forward to sharing the results of these studies with oncologists and cancer researchers at this year’s ASH meeting.”
POSTER PRESENTATIONS
Title: Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort
Date & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract: 1539
Location: San Diego Convention Center – Hall GH
Presenter: Shireen Vali
Title: WT1 and BCORL1 Identified by Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)
Date & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract: 1538
Location: San Diego Convention Center - Hall GH
Presenter: Shireen Vali
Title: Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study
Date & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Poster Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract: 1540
Location: San Diego Convention Center – Hall GH
Presenter: Shireen Vali
Title: Computational Modeling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
Date & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Abstract: 1911
Location: San Diego Convention Center - Hall GH
Presenter: Aneel Paulus
Title: Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study
Date & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract: 1541
Location: San Diego Convention Center - Hall GH
Presenter: Shireen Vali
Title: Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modeling Multiple Myeloma Algorithm
Date & Time: Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Abstract: 1893
Location: San Diego Convention Center – Hall GH
Presenter: Justin King
Title: Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study
Date & Time: Sunday, December 2, 2018 from 6:00 PM-8:00 PM
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Abstract: 3086
Location: San Diego Convention Center – Hall GH
Presenter: Shireen Vali
Title: Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System
Date & Time: Sunday, December 2, 2018 from 6:00 PM-8:00 PM
Poster Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Abstract: 3087
Location: San Diego Convention Center - Hall GH
Presenter: Lubomir Minarik
Title: Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modeling of Genomics and Proteomics
Date & Time: Sunday, December 2, 2018 from 6:00 PM-8:00 PM
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Abstract: 3193
Location: San Diego Convention Center – Hall GH
Presenter: Shireen Vali
Title: AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow
Date & Time: Monday, December 3, 2018 from 6:00 PM-8:00 PM
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III
Abstract: 4034
Location: San Diego Convention Center - Hall GH
Presenter: Shireen Vali
Cellworks is transforming personalized cancer therapy through AI-driven biosimulation software models that represent bio molecular and physiological pathways using the genomic data of each patient. Cellworks personalized medicine predictions help transform lives through the early adoption of successful therapies, while saving time and cost across the healthcare ecosystem. Cellworks also benefits the biopharma industry through virtual clinical trials, improved target identification, lead validation and the ability to repurpose and rescue drugs.
About Cellworks Group, Inc.
Cellworks Group, Inc. is a world leader in Precision Medicine in the key therapeutic areas of Oncology and Immunology. Cellworks’ unique AI-driven biosimulation platform is a unified representation of biological knowledge, curated from heterogeneous datasets, applied to finding cures. Backed by Sequoia Capital and Artiman Ventures, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers, and software technologists working towards a common goal – attacking serious diseases to improve the lives of patients. The company is based in San Jose, California and has a research and development facility in Bangalore, India. For more information, visit www.cellworks.life, and follow us on Twitter @cellworkslife.
All trademarks and registered trademarks in this document are the properties of their respective owners.
Media Contacts:
Barbara Reichert, Reichert Communications, LLC, Barbara@reichertcom.com or 650-548-1002
Michele Macpherson, Chief Business Officer, Cellworks Group, Inc., michele.macpherson@cellworksgroup.com